Clinical trials: Antibody
Asthma Attack, Asthma
Benralizumab Initiated During Severe Asthma Attack
Approximately 300 million people have asthma worldwide and 400,000 people died from asthma globally in 2015 (GINA Asthma). Singapore's asthma mortality and hospitalisation rates are several times higher than OECD countries.
- Trial name
- NCT04617171
- Testing
- Benralizumab 30 MG/ML [Fasenra]
- Where
- Singapore
- Volunteers
- 128 people
- Sponsor
- Singapore General Hospital
Systemic Lupus Erythematosus
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to…
- Trial name
- NCT04179032
- Testing
- Belimumab
- Where
- 11 sites in United States, Argentina and 5 more
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.
- Trial name
- NCT00528333
- Testing
- Lintuzumab (SGN-33), Low dose cytarabine
- Where
- 20 sites in United States
- Volunteers
- 211 people
- Sponsor
- Seagen Inc.
Intrahepatic Cholangiocarcinoma
Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC
TOPAZ-1 phase III trail demonstrated that the addition of immune checkpoint inhibitor anti-PD-L1 antibody improved progression-free survival (PFS) and overall survival (OS) compared to Gem/Cis alone.
- Trial name
- NCT05781958
- Testing
- Cadonilimab+Gem/Cis
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shen Feng
Neonatal Sepsis
Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis
Majority of healthcare authorities believe that due to the methodological weakness and small number of patients in conducted therapeutic trials, the evidences are insufficient to support the efficacy of intravenous immunoglobulin…
- Trial name
- NCT02954926
- Testing
- IVIG
- Where
- Iran
- Volunteers
- 92 people
- Sponsor
- Hormozgan University of Medical Sciences
Increased Drug Resistance, Asymptomatic Infection
Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases and Malaria Antibody Kinetic
Detection of the drug resistance molecular markers for falciparum and vivax in Longitudinal follow-up samples collected in Shwegyin Township, Bago Region that is Artemisinin Resistance Containment Tier I.
- Conditions
- Increased Drug Resistance, Asymptomatic Infection, Malaria
- Trial name
- NCT02708199
- Volunteers
- 1,179 people, healthy volunteers welcome
- Sponsor
- Department of Medical Research, Lower Myanmar
Rectal Cancer
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
This is a phase II, prospective, open label, one-center study for evaluation of the addition of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced rectal cancer patients.
- Trial name
- NCT03921684
- Testing
- Capecitabine, Radiation therapy, mFOLFOX6
- Where
- Israel
- Volunteers
- 29 people
- Sponsor
- Baruch Brenner
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
IgA Nephropathy (IgAN)
Mediators of Loin Pain in IgA Nephropathy
The goal of this observational study is to learn about loin pain in people with Immunoglobulin A nephropathy (IgAN). The main question it aims to answer is: What changes occur in the kidneys, urine, and blood when people with…
- Trial name
- LO-PAIgN (NCT07649538)
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Leicester
Patients With Cancer
Radioimmunotherapy With 131I-L19SIP in Patients With Cancer
The aim of this Study Protocol is to provide a basis for the clinical development of 131I-L19SIP as an anti-cancer therapeutic agent, following the promising results of a Phase I study.
- Trial name
- NCT01242943
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT)
- Where
- 4 sites in Italy, United Kingdom
- Volunteers
- 34 people
- Sponsor
- Philogen S.p.A.
Cancer
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended…
- Trial name
- NCT05040932
- Testing
- YH004
- Where
- 3 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Covid19
COVID-19 IgG Antibodies in the Serum of Recovered Patients
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in China, in December 2019 and is now spreading worldwide and poses a great…
- Trial name
- NCT04470414
- Testing
- IgG antibodies immunoassay
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Solid Tumors, Sarcomas
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.
- Trial name
- NCT07374848
- Testing
- ZL-6201
- Where
- 8 sites in United States, China
- Volunteers
- 180 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Healthy
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Many plasma donation centers have Tetanus immunization programs that are implemented in order to collect plasma with high levels of tetanus antibodies.
- Trial name
- NCT02673255
- Testing
- Tetanus and Diphtheria (Td) Vaccine
- Where
- 4 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Biomat USA, Inc.
Hematologic Malignancies
Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation
This study will determine the Maximal Tolerated Dose if any and the recommended dose for phase 2 of monalizumab, a monoclonal antibody directed against the CD94/NKG2A receptor, after allogenic stem cell transplantation.
- Trial name
- PIRAT (NCT02921685)
- Testing
- Monalizumab
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Institut Paoli-Calmettes
Infection
Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS
This study was aimed evaluate long-term immunity response by neutralizing antibody test of adults in high risk population of HFRS .
- Trial name
- NCT02360514
- Testing
- Hantavax injection
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
This phase I trial is to find out the best dose, possible benefits and/or side effects of 90Y-DOTA-anti-CD25 basiliximab given together with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) in treating…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
- Trial name
- NCT05139004
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Dermatitis, Atopic
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the efficacy of 611 in Chinese Adolescents with moderate to severe atopic dermatitis.
- Trial name
- NCT07042126
- Testing
- 611
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Non-allergic Rhinitis
The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population
The purpose of this study to determine the therapeutic response of non-allergic rhinitis patients that have been subtyped as non-allergic rhinitis with local IgE elevation or non-allergic rhinopathy to intranasal capsaicin based…
- Trial name
- NCT05093478
- Testing
- Intranasal capsaicin, topical lidocaine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center, Houston
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.